BioCentury
ARTICLE | Finance

Cross court

How Ra courted crossover investors for its series B

August 17, 2015 7:00 AM UTC

For private companies looking to court crossover investors, the lesson from Ra Pharmaceuticals Inc.'s $58.5 million series B round is that having a well-connected board is paramount.

"We had a board meeting last September when the discussion was about socializing the message," said President and CEO Doug Treco. "I wouldn't call it testing the waters; we were just out there getting more people aware of the story for the future." ...